

Olli Kallioniemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3942583/publications.pdf>

Version: 2024-02-01

438
papers

52,432
citations

1893

102
h-index

1505

219
g-index

460
all docs

460
docs citations

460
times ranked

50887
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290. | 3.7 | 4 |
| 2 | Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401. | 9.4 | 73 |
| 3 | Multimomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health. <i>Cell Systems</i> , 2022, 13, 241-255.e7. | 6.2 | 8 |
| 4 | Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , 2022, 2, 172-181. | 1.7 | 2 |
| 5 | Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. <i>Nature Communications</i> , 2022, 13, 1691. | 12.8 | 20 |
| 6 | E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. <i>Molecular Oncology</i> , 2022, 16, 2312-2329. | 4.6 | 4 |
| 7 | The transcriptome-wide landscape of molecular subtype-specific <i>scp</i> mRNA expression profiles in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 580-588. | 4.1 | 9 |
| 8 | STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. <i>Translational Oncology</i> , 2021, 14, 101027. | 3.7 | 9 |
| 9 | High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 482-494. | 3.0 | 4 |
| 10 | Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71. | 5.4 | 12 |
| 11 | The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543. | 4.6 | 7 |
| 12 | Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish Adults. <i>Journal of Nutrition</i> , 2021, 151, 281-292. | 2.9 | 8 |
| 13 | FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <i>Scientific Reports</i> , 2021, 11, 23565. | 3.3 | 6 |
| 14 | Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538. | 3.5 | 19 |
| 15 | Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. <i>Cell Death and Disease</i> , 2020, 11, 790. | 6.3 | 38 |
| 16 | KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784. | 7.2 | 6 |
| 17 | Building an international consortium for tracking coronavirus health status. <i>Nature Medicine</i> , 2020, 26, 1161-1165. | 30.7 | 23 |
| 18 | Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604. | 4.1 | 68 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , 2020, 4, 274-286. | 5.2 | 38 |
| 20 | Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366. | 5.1 | 29 |
| 21 | Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. <i>Prostate</i> , 2019, 79, 1505-1513. | 2.3 | 23 |
| 22 | Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , 2019, 33, 2548-2553. | 7.2 | 25 |
| 23 | Individual and stable autoantibody repertoires in healthy individuals. <i>Autoimmunity</i> , 2019, 52, 1-11. | 2.6 | 52 |
| 24 | Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. <i>British Journal of Cancer</i> , 2019, 120, 435-443. | 6.4 | 24 |
| 25 | Characterization of farnesyl diphosphate farnesyl transferase 1 (<i>FDFT1</i>) expression in cancer. <i>Personalized Medicine</i> , 2019, 16, 51-65. | 1.5 | 17 |
| 26 | Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. <i>Leukemia</i> , 2019, 33, 1570-1582. | 7.2 | 43 |
| 27 | Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 63-78. | 3.0 | 20 |
| 28 | Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 1676-1687. | 7.0 | 14 |
| 29 | T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , 2019, 104, 338-346. | 3.5 | 38 |
| 30 | High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4641-4641. | 1.4 | 1 |
| 31 | Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling. , 2019, , . | | 0 |
| 32 | Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling. , 2019, , . | | 0 |
| 33 | Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from <i>Kras</i> -driven lung tumours. <i>Journal of Pathology</i> , 2018, 245, 101-113. | 4.5 | 19 |
| 34 | Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 3002-3005. | 1.3 | 0 |
| 35 | Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2220-2230. | 3.6 | 13 |
| 36 | ITGB1-dependent upregulation of Caveolin-1 switches TGF β 2 signalling from tumour-suppressive to oncogenic in prostate cancer. <i>Scientific Reports</i> , 2018, 8, 2338. | 3.3 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806. | 7.0 | 177 |
| 38 | Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787. | 7.2 | 75 |
| 39 | Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2060-2071. | 4.1 | 33 |
| 40 | PD-L1 ⁺ tumor-associated macrophages and PD-1 ⁺ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. <i>Haematologica</i> , 2018, 103, 1908-1914. | 3.5 | 64 |
| 41 | Association of tamoxifen resistance and lipid reprogramming in breast cancer. <i>BMC Cancer</i> , 2018, 18, 850. | 2.6 | 113 |
| 42 | Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. <i>Molecular Oncology</i> , 2018, 12, 1639-1655. | 4.6 | 40 |
| 43 | Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. <i>Leukemia</i> , 2018, 32, 1643-1656. | 7.2 | 75 |
| 44 | Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. <i>Blood</i> , 2018, 132, 2763-2763. | 1.4 | 1 |
| 45 | Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264. | 1.4 | 5 |
| 46 | Predictive Response Biomarkers for BET Inhibitors in AML. <i>Blood</i> , 2018, 132, 2749-2749. | 1.4 | 2 |
| 47 | Abstract 5302: Phenotypic heterogeneity of patient-derived tumor cells visualized by unsupervised analysis in cell-based personalized drug testing. , 2018, , . | | 0 |
| 48 | Abstract 3883: Gene expression predictsex vivodrug sensitivity in acute myeloid leukemia. , 2018, , . | | 0 |
| 49 | Abstract 5029: Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models. , 2018, , . | | 1 |
| 50 | Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine. , 2018, , . | | 0 |
| 51 | Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling. , 2018, , . | | 0 |
| 52 | Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. <i>Blood</i> , 2018, 132, 2774-2774. | 1.4 | 0 |
| 53 | Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327. | 1.9 | 74 |
| 54 | Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630. | 1.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | <i>PLA2G7</i> associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 123-138. | 3.0 | 20 |
| 56 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , 2017, 130, 789-802. | 1.4 | 90 |
| 57 | Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. <i>Molecular Oncology</i> , 2017, 11, 1156-1171. | 4.6 | 15 |
| 58 | Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. <i>Cell Reports</i> , 2017, 18, 673-684. | 6.4 | 47 |
| 59 | Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. <i>Scientific Reports</i> , 2017, 7, 15580. | 3.3 | 120 |
| 60 | Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 1048-1058. | 7.2 | 11 |
| 61 | Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. <i>Leukemia</i> , 2017, 31, 1187-1195. | 7.2 | 44 |
| 62 | KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 98, 30-39. | 4.0 | 59 |
| 63 | HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309. | 7.2 | 61 |
| 64 | Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 51-57. | 7.2 | 42 |
| 65 | Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268. | 5.2 | 25 |
| 66 | Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , 2017, 7, 3824-3841. | 10.0 | 167 |
| 67 | The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. <i>BMC Genomics</i> , 2017, 18, 629. | 2.8 | 42 |
| 68 | Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 185-198. | 1.8 | 23 |
| 69 | Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854. | 1.4 | 1 |
| 70 | Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615. | 1.8 | 13 |
| 71 | Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer. , 2017, , . | | 0 |
| 72 | Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer. , 2017, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia. , 2017, , . | | 0 |
| 74 | Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling. , 2017, , . | | 0 |
| 75 | Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells. , 2017, , . | | 0 |
| 76 | A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. <i>Oncotarget</i> , 2016, 7, 28510-28522. | 1.8 | 15 |
| 77 | Consistency in drug response profiling. <i>Nature</i> , 2016, 540, E5-E6. | 27.8 | 76 |
| 78 | Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. <i>BMC Cancer</i> , 2016, 16, 378. | 2.6 | 11 |
| 79 | Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. <i>Bioinformatics</i> , 2016, 32, i455-i463. | 4.1 | 87 |
| 80 | Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. <i>European Urology</i> , 2016, 69, 1120-1128. | 1.9 | 53 |
| 81 | Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. <i>PLoS Pathogens</i> , 2016, 12, e1005424. | 4.7 | 30 |
| 82 | Intrinsic resistance to PIM kinase inhibition in AML through p38 β -mediated feedback activation of mTOR signaling. <i>Oncotarget</i> , 2016, 7, 37407-37419. | 1.8 | 16 |
| 83 | Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. <i>Journal of Clinical Oncology</i> , 2016, 34, 604-604. | 1.6 | 0 |
| 84 | Abstract 2935: Systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines. , 2016, , . | | 0 |
| 85 | Abstract 1517: Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies. , 2016, , . | | 0 |
| 86 | Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML. , 2016, , . | | 0 |
| 87 | Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing. , 2016, , . | | 1 |
| 88 | Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. <i>Blood</i> , 2016, 128, 1897-1897. | 1.4 | 0 |
| 89 | High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. <i>Journal of Molecular Biochemistry</i> , 2016, 5, 12-22. | 0.1 | 7 |
| 90 | Circulating tumor <scp>DNA</scp> in earlyâ€stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?. <i>EMBO Molecular Medicine</i> , 2015, 7, 994-995. | 6.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 91 | Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309. | 6.2 | 19 |
| 92 | Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data. <i>Bioinformatics</i> , 2015, 31, 3815-3821. | 4.1 | 31 |
| 93 | Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 3274-3283. | 3.8 | 19 |
| 94 | miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. <i>European Urology</i> , 2015, 68, 581-588. | 1.9 | 35 |
| 95 | Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. <i>Nature</i> , 2015, 519, 102-105. | 27.8 | 207 |
| 96 | The impact of low-frequency and rare variants on lipid levels. <i>Nature Genetics</i> , 2015, 47, 589-597. | 21.4 | 310 |
| 97 | MicroRNA-135b regulates ER, AR and HIF1AN and affects breast and prostate cancer cell growth. <i>Molecular Oncology</i> , 2015, 9, 1287-1300. | 4.6 | 45 |
| 98 | Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S8-S9. | 0.4 | 0 |
| 99 | Androgen receptor-interacting protein <sc>HSPBAP1</sc> facilitates growth of prostate cancer cells in androgen-deficient conditions. <i>International Journal of Cancer</i> , 2015, 136, 2535-2545. | 5.1 | 10 |
| 100 | Abstract 3746: Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites. , 2015, , . | | 1 |
| 101 | Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs. , 2015, , . | | 0 |
| 102 | Abstract 1698: Systems pathology for characterization of cancer model systems in a multicenter IMI-PREDECT project. , 2015, , . | | 0 |
| 103 | Abstract 676: Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion. , 2015, , . | | 0 |
| 104 | Abstract 207: Caveolin-1 drives oncogenic TGF β 2 effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples. , 2015, , . | | 0 |
| 105 | BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. <i>Blood</i> , 2015, 126, 2462-2462. | 1.4 | 0 |
| 106 | JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. <i>Blood</i> , 2015, 126, 867-867. | 1.4 | 0 |
| 107 | Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e96767. | 2.5 | 49 |
| 108 | Genetic Instability of Influenza pH1N1 Viruses. <i>Genome Announcements</i> , 2014, 2, . | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 109 | A novel transcript, <i>VNN1</i> , as a biomarker for colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2077-2084. | 5.1 | 18 |
| 110 | Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1043-e1043. | 6.3 | 25 |
| 111 | Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. <i>Bioinformatics</i> , 2014, 30, i497-i504. | 4.1 | 33 |
| 112 | Akt Inhibitor MK2206 Prevents Influenza pH1N1 Virus Infection <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3689-3696. | 3.2 | 38 |
| 113 | Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. <i>Oncogene</i> , 2014, 33, 3538-3549. | 5.9 | 34 |
| 114 | High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. <i>Molecular Oncology</i> , 2014, 8, 93-104. | 4.6 | 146 |
| 115 | Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells. <i>Science</i> , 2014, 343, 88-91. | 12.6 | 387 |
| 116 | 684: Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers. <i>European Journal of Cancer</i> , 2014, 50, S164. | 2.8 | 0 |
| 117 | 826: Primary T-prolymphocytic leukemia (T-PLL) cells are sensitive to BCL-2 and HDAC inhibitors: Results from high-throughput ex vivo drug testing. <i>European Journal of Cancer</i> , 2014, 50, S200. | 2.8 | 1 |
| 118 | 273: Androgen receptor interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. <i>European Journal of Cancer</i> , 2014, 50, S64. | 2.8 | 0 |
| 119 | Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 2347-2359. | 5.4 | 101 |
| 120 | Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742. | 7.2 | 90 |
| 121 | A community effort to assess and improve drug sensitivity prediction algorithms. <i>Nature Biotechnology</i> , 2014, 32, 1202-1212. | 17.5 | 653 |
| 122 | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193. | 3.3 | 243 |
| 123 | Landscape of Mutations in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2367-2367. | 1.4 | 1 |
| 124 | Abstract 982: Analysis of clonal evolution of leukemia in vivo following novel targeted treatments. , 2014, , . | | 0 |
| 125 | Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs. , 2014, , . | | 0 |
| 126 | Abstract 4184: Drug set enrichment analysis : A computational approach to identify functional drug sets. , 2014, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. <i>Blood</i> , 2014, 124, 917-917. | 1.4 | 0 |
| 128 | Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505. | 1.4 | 0 |
| 129 | The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. <i>Blood</i> , 2014, 124, 2203-2203. | 1.4 | 3 |
| 130 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046. | 1.4 | 3 |
| 131 | Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. <i>Blood</i> , 2014, 124, 1022-1022. | 1.4 | 0 |
| 132 | AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. <i>Blood</i> , 2014, 124, 2163-2163. | 1.4 | 1 |
| 133 | A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. <i>Blood</i> , 2014, 124, 3139-3139. | 1.4 | 0 |
| 134 | Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. <i>Carcinogenesis</i> , 2013, 34, 2000-2009. | 2.8 | 5 |
| 135 | Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK1±/IKK1². <i>Oncogene</i> , 2013, 32, 4892-4902. | 5.9 | 121 |
| 136 | The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. <i>Molecular Oncology</i> , 2013, 7, 392-401. | 4.6 | 80 |
| 137 | Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429. | 9.4 | 334 |
| 138 | Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550. | 1.4 | 252 |
| 139 | Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168. | 6.2 | 56 |
| 140 | ARLTS1 and Prostate Cancer Risk - Analysis of Expression and Regulation. <i>PLoS ONE</i> , 2013, 8, e72040. | 2.5 | 12 |
| 141 | Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. <i>PLoS ONE</i> , 2013, 8, e74293. | 2.5 | 26 |
| 142 | High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e77232. | 2.5 | 154 |
| 143 | Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863. | 1.4 | 5 |
| 144 | Functional Profiling of Precursor MicroRNAs Identifies MicroRNAs Essential for Glioma Proliferation. <i>PLoS ONE</i> , 2013, 8, e60930. | 2.5 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 145 | High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. <i>Oncotarget</i> , 2013, 4, 48-63. | 1.8 | 95 |
| 146 | Abstract 2107: Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines.. , 2013, , . | | 0 |
| 147 | Abstract 65: Comprehensive ex vivo drug sensitivity testing combined with in depth molecular profiling of AML patients cells provides individualized treatment strategies and reveals mechanisms of drug resistance.. , 2013, , . | | 0 |
| 148 | Abstract 5588: Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions.. , 2013, , . | | 0 |
| 149 | Abstract 721: Multiplexed systems pathology for in-depth analysis of the tumor microenvironment: a strong correlation between pAkt and androgen receptor in the epithelial component of prostate cancer.. , 2013, , . | | 0 |
| 150 | Abstract A34: Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer. , 2013, , . | | 0 |
| 151 | Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. <i>Blood</i> , 2013, 122, 1668-1668. | 1.4 | 0 |
| 152 | Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. <i>Blood</i> , 2013, 122, 3828-3828. | 1.4 | 0 |
| 153 | Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482. | 1.4 | 0 |
| 154 | High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. <i>Blood</i> , 2013, 122, 2719-2719. | 1.4 | 0 |
| 155 | Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis. <i>Molecular Cancer Research</i> , 2012, 10, 597-604. | 3.4 | 35 |
| 156 | A functional genetic screen reveals new regulators of β 1-integrin activity. <i>Journal of Cell Science</i> , 2012, 125, 649-661. | 2.0 | 38 |
| 157 | c-Jun N-Terminal Kinase Phosphorylation of MARCKSL1 Determines Actin Stability and Migration in Neurons and in Cancer Cells. <i>Molecular and Cellular Biology</i> , 2012, 32, 3513-3526. | 2.3 | 68 |
| 158 | HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. <i>Oncogene</i> , 2012, 31, 1299-1310. | 5.9 | 33 |
| 159 | Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913. | 27.0 | 681 |
| 160 | Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. <i>Oncogene</i> , 2012, 31, 2075-2089. | 5.9 | 44 |
| 161 | Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. <i>Oncogene</i> , 2012, 31, 3597-3606. | 5.9 | 48 |
| 162 | Interaction with ErbB4 Promotes Hypoxia-inducible Factor-1 α Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 9659-9671. | 3.4 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 163 | Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. <i>British Journal of Cancer</i> , 2012, 106, 99-106. | 6.4 | 141 |
| 164 | An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. <i>Oncogene</i> , 2012, 31, 2090-2100. | 5.9 | 111 |
| 165 | 338 The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells. <i>European Journal of Cancer</i> , 2012, 48, S82-S83. | 2.8 | 0 |
| 166 | 589 Precursor MicroRNA Functional Profiling Identifies MicroRNAs Essential for Glioblastoma Proliferation. <i>European Journal of Cancer</i> , 2012, 48, S140. | 2.8 | 0 |
| 167 | 681 Aneuploidy Facilitates Oncogenic Transformation Via Specific Genetic Alterations. <i>European Journal of Cancer</i> , 2012, 48, S161. | 2.8 | 0 |
| 168 | 825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. <i>European Journal of Cancer</i> , 2012, 48, S198. | 2.8 | 0 |
| 169 | The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. <i>Breast Cancer Research</i> , 2012, 14, R113. | 5.0 | 49 |
| 170 | MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. <i>Neoplasia</i> , 2012, 14, 868-IN21. | 5.3 | 124 |
| 171 | Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. <i>Oncogene</i> , 2012, 31, 3444-3456. | 5.9 | 112 |
| 172 | Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. <i>BMC Bioinformatics</i> , 2012, 13, 112. | 2.6 | 16 |
| 173 | 461 Identification of Personalized Therapeutic Strategies and Associated Biomarkers in Adult Acute Myeloid Leukemia Using a Functional Drug Sensitivity and Resistance Testing Platform. <i>European Journal of Cancer</i> , 2012, 48, 142-143. | 2.8 | 0 |
| 174 | Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer—Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. <i>Journal of Proteome Research</i> , 2012, 11, 850-860. | 3.7 | 68 |
| 175 | Identification of MicroRNAs Inhibiting TGF- β -Induced IL-11 Production in Bone Metastatic Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e37361. | 2.5 | 72 |
| 176 | High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e39801. | 2.5 | 54 |
| 177 | 15- α -Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. <i>Journal of Pathology</i> , 2012, 226, 674-686. | 4.5 | 32 |
| 178 | Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , 2012, 72, 789-802. | 2.3 | 30 |
| 179 | Abstract 2984: A comprehensive bioinformatic analysis of the representativity of 460 cancer cell lines as model systems for 88 different clinical cancer types. , 2012, , . | | 1 |
| 180 | Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2. , 2012, , . | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 181 | Abstract 4580: Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling. , 2012, , . | | 1 |
| 182 | Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. , 2012, , . | | 1 |
| 183 | Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871. | 1.4 | 2 |
| 184 | Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms. PLoS ONE, 2012, 7, e48745. | 2.5 | 72 |
| 185 | Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma. PLoS ONE, 2012, 7, e50819. | 2.5 | 9 |
| 186 | Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells. PLoS ONE, 2012, 7, e51470. | 2.5 | 24 |
| 187 | Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. , 2012, , . | | 0 |
| 188 | Abstract 3188: Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. , 2012, , . | | 0 |
| 189 | Abstract 334: Identification of novel regulatory genes controlling epithelial to mesenchymal transition in cultured breast cancer cells. , 2012, , . | | 0 |
| 190 | High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288. | 1.4 | 1 |
| 191 | Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. Blood, 2012, 120, 1302-1302. | 1.4 | 0 |
| 192 | SHARPIN is an endogenous inhibitor of β 1-integrin activation. Nature Cell Biology, 2011, 13, 1315-1324. | 10.3 | 184 |
| 193 | Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biology, 2011, 12, R6. | 9.6 | 301 |
| 194 | Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Medicine, 2011, 3, 63. | 8.2 | 12 |
| 195 | Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. American Journal of Pathology, 2011, 178, 525-536. | 3.8 | 102 |
| 196 | Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nature Reviews Clinical Oncology, 2011, 8, 142-150. | 27.6 | 277 |
| 197 | Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells. PLoS ONE, 2011, 6, e26595. | 2.5 | 8 |
| 198 | SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948. | 3.7 | 209 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 199 | MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. <i>European Urology</i> , 2011, 59, 671-681. | 1.9 | 401 |
| 200 | Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 421-430. | 2.5 | 222 |
| 201 | Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. <i>BioData Mining</i> , 2011, 4, 5. | 4.0 | 5 |
| 202 | A cell spot microarray method for production of high density siRNA transfection microarrays. <i>BMC Genomics</i> , 2011, 12, 162. | 2.8 | 50 |
| 203 | Androgen regulation of microRNAs in prostate cancer. <i>Prostate</i> , 2011, 71, 604-614. | 2.3 | 144 |
| 204 | The miR-15a-miR-16 locus is homozygously deleted in a subset of prostate cancers. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 499-509. | 2.8 | 42 |
| 205 | Identification of miR-193b Targets in Breast Cancer Cells and Systems Biological Analysis of Their Functional Impact. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.005322. | 3.8 | 60 |
| 206 | KRAS Oncogene Rearrangements and Gene Fusions: Unexpected Rare Encounters in Late-Stage Prostate Cancers: Table 1.. <i>Cancer Discovery</i> , 2011, 1, 12-13. | 9.4 | 3 |
| 207 | Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. <i>Cancer Research</i> , 2011, 71, 3236-3245. | 0.9 | 444 |
| 208 | Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 1956-1967. | 0.9 | 244 |
| 209 | Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. <i>EMBO Journal</i> , 2011, 30, 3962-3976. | 7.8 | 318 |
| 210 | On the organization of bioinformatics core services in biology-based research institutes. <i>Bioinformatics</i> , 2011, 27, 1345-1345. | 4.1 | 9 |
| 211 | Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. , 2011, , . | | 3 |
| 212 | Abstract 52: A new method to interpret gene expression microarray data for individual tumors by profile alignment against a reference dataset of 10,000 samples. , 2011, , . | | 1 |
| 213 | miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. <i>PLoS ONE</i> , 2011, 6, e16915. | 2.5 | 278 |
| 214 | GTI: A Novel Algorithm for Identifying Outlier Gene Expression Profiles from Integrated Microarray Datasets. <i>PLoS ONE</i> , 2011, 6, e17259. | 2.5 | 29 |
| 215 | Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. <i>Oncotarget</i> , 2011, 2, 1176-1190. | 1.8 | 77 |
| 216 | Abstract 3800: HES6 gene is a strong glioma biomarker and a key transcriptional regulator needed for cancer cell growth. , 2011, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 217 | Abstract 2597: PLA2G7 associates with aggressive prostate cancer in vivo and regulates prostate cancer cell migration and adhesion in vitro. , 2011, , . | | 0 |
| 218 | Abstract 4836: In vitro drug sensitivity testing along with full genome and transcriptome sequencing and phosphoproteomics: Comprehensive “next-generation” molecular oncology portrait of a sarcoma for facilitating treatment decisions. , 2011, , . | | 0 |
| 219 | Abstract 4850: Paired-end RNA-sequencing based identification of 24 novel fusion genes in breast cancer. , 2011, , . | | 0 |
| 220 | Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. , 2011, , . | | 1 |
| 221 | Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer. , 2011, , . | | 0 |
| 222 | Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487. | 1.4 | 0 |
| 223 | Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. Blood, 2011, 118, 936-936. | 1.4 | 6 |
| 224 | Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. Experimental Cell Research, 2010, 316, 1610-1624. | 2.6 | 30 |
| 225 | Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes and Cancer, 2010, 49, 1062-1069. | 2.8 | 172 |
| 226 | International network of cancer genome projects. Nature, 2010, 464, 993-998. | 27.8 | 2,114 |
| 227 | A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses. PLoS ONE, 2010, 5, e10431. | 2.5 | 299 |
| 228 | Analysis of Kinase Gene Expression Patterns across 5681 Human Tissue Samples Reveals Functional Genomic Taxonomy of the Kinome. PLoS ONE, 2010, 5, e15068. | 2.5 | 44 |
| 229 | Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 3175-3185. | 4.1 | 80 |
| 230 | Fibroblast Growth Factor Receptor 4 Regulates Tumor Invasion by Coupling Fibroblast Growth Factor Signaling to Extracellular Matrix Degradation. Cancer Research, 2010, 70, 7851-7861. | 0.9 | 49 |
| 231 | Cancer Genomes. Clinical Chemistry, 2010, 56, 1660-1664. | 3.2 | 5 |
| 232 | <i>FZD4</i> as a Mediator of <i>ERG</i> Oncogene-Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells. Cancer Research, 2010, 70, 6735-6745. | 0.9 | 229 |
| 233 | Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. Epigenomics, 2010, 2, 683-689. | 2.1 | 6 |
| 234 | 558 Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. European Journal of Cancer, Supplement, 2010, 8, 177. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 235 | Integrative Functional Genomics Analysis of Sustained Polyploidy Phenotypes in Breast Cancer Cells Identifies an Oncogenic Profile for GINS2. <i>Neoplasia</i> , 2010, 12, 877-IN14. | 5.3 | 44 |
| 236 | Abstract 1953: Functional identification of microRNA targets by integrated proteomics and microarray profiling: miR-193b in breast cancer. , 2010, , . | | 0 |
| 237 | Abstract 2072: Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. , 2010, , . | | 0 |
| 238 | Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 6570-6581. | 7.0 | 33 |
| 239 | Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. <i>Carcinogenesis</i> , 2009, 30, 1032-1040. | 2.8 | 49 |
| 240 | High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2009, 15, 6070-6078. | 7.0 | 185 |
| 241 | CIP2A Is Associated with Human Breast Cancer Aggressivity. <i>Clinical Cancer Research</i> , 2009, 15, 5092-5100. | 7.0 | 205 |
| 242 | Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations. <i>BMC Bioinformatics</i> , 2009, 10, S24. | 2.6 | 35 |
| 243 | Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 227-239. | 2.9 | 9 |
| 244 | Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. <i>BMC Medical Genomics</i> , 2009, 2, 26. | 1.5 | 8 |
| 245 | Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. <i>Oncogene</i> , 2009, 28, 3926-3936. | 5.9 | 205 |
| 246 | Critical Comparison of Virtual Screening Methods against the MUV Data Set. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2168-2178. | 5.4 | 42 |
| 247 | The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517. | 2.8 | 79 |
| 248 | A Decade of Cancer Gene Profiling: From Molecular Portraits to Molecular Function. <i>Methods in Molecular Biology</i> , 2009, 576, 61-87. | 0.9 | 13 |
| 249 | Role of ErbB4 in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 259-268. | 2.7 | 121 |
| 250 | Functional evidence implicating S100P in prostate cancer progression. <i>International Journal of Cancer</i> , 2008, 123, 330-339. | 5.1 | 61 |
| 251 | Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG α -positive prostate cancer. <i>International Journal of Cancer</i> , 2008, 123, 2774-2781. | 5.1 | 60 |
| 252 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. <i>British Journal of Cancer</i> , 2008, 98, 1457-1466. | 6.4 | 461 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 253 | Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. <i>Genome Biology</i> , 2008, 9, R139. | 9.6 | 234 |
| 254 | Application of Active and Kinase-Deficient Kinome Collection for Identification of Kinases Regulating Hedgehog Signaling. <i>Cell</i> , 2008, 133, 537-548. | 28.9 | 171 |
| 255 | P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells. <i>Cancer Treatment Reviews</i> , 2008, 34, 22. | 7.7 | 2 |
| 256 | Integrin Trafficking Regulated by Rab21 Is Necessary for Cytokinesis. <i>Developmental Cell</i> , 2008, 15, 371-385. | 7.0 | 177 |
| 257 | Cancer genome analysis: a landscape seen from many angles. <i>Drug Discovery Today Disease Mechanisms</i> , 2007, 4, 269-276. | 0.8 | 0 |
| 258 | Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. <i>Oncogene</i> , 2007, 26, 3846-3856. | 5.9 | 155 |
| 259 | ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. <i>Nature Methods</i> , 2007, 4, 13-17. | 19.0 | 231 |
| 260 | A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007, 8, 84. | 2.8 | 39 |
| 261 | Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. <i>Carcinogenesis</i> , 2006, 28, 1040-1045. | 2.8 | 21 |
| 262 | TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. <i>Cancer Research</i> , 2006, 66, 10242-10246. | 0.9 | 209 |
| 263 | The weibull distribution based normalization method for affymetrix gene expression microarray data. , 2006, , . | | 0 |
| 264 | BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. <i>European Journal of Human Genetics</i> , 2006, 14, 167-172. | 2.8 | 41 |
| 265 | Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. <i>Oncogene</i> , 2006, 25, 6997-7008. | 5.9 | 88 |
| 266 | Integrated breast cancer genomics. <i>Cancer Cell</i> , 2006, 10, 453-454. | 16.8 | 5 |
| 267 | Human Protein Atlas charts a diverse terrain. <i>Trends in Biotechnology</i> , 2006, 24, 195-197. | 9.3 | 25 |
| 268 | Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors. <i>Cancer Research</i> , 2006, 66, 743-747. | 0.9 | 54 |
| 269 | Novel Genomic Aberrations in Testicular Germ Cell Tumors by Array-CGH, and Associated Gene Expression Changes. <i>Analytical Cellular Pathology</i> , 2006, 28, 315-326. | 1.4 | 54 |
| 270 | Application of Microarray Technologies for Translational Genomics. <i>Biological and Medical Physics Series</i> , 2005, , 361-374. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 271 | Functional genomics and transcriptomics of prostate cancer: promises and limitations. <i>BJU International</i> , 2005, 96, 10-15. | 2.5 | 7 |
| 272 | Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. <i>International Journal of Cancer</i> , 2005, 113, 575-580. | 5.1 | 97 |
| 273 | Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. <i>Human Genetics</i> , 2005, 116, 43-50. | 3.8 | 25 |
| 274 | A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. <i>Human Genetics</i> , 2005, 117, 307-316. | 3.8 | 30 |
| 275 | EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 6450-6458. | 7.0 | 81 |
| 276 | Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. <i>Journal of Medical Genetics</i> , 2005, 42, 602-603. | 3.2 | 121 |
| 277 | Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal Development. <i>Cancer Research</i> , 2005, 65, 5588-5598. | 0.9 | 194 |
| 278 | Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. <i>Breast Cancer Research</i> , 2005, 7, 1. | 5.0 | 1 |
| 279 | NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer. <i>Analytical Cellular Pathology</i> , 2005, 27, 169-173. | 1.4 | 7 |
| 280 | Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 2344-2350. | 7.0 | 42 |
| 281 | Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. <i>Nature Genetics</i> , 2004, 36, 979-983. | 21.4 | 180 |
| 282 | Genome-wide scanning for linkage in Finnish breast cancer families. <i>European Journal of Human Genetics</i> , 2004, 12, 98-104. | 2.8 | 27 |
| 283 | Claes Lundsteen in Memoriam. <i>European Journal of Human Genetics</i> , 2004, 12, 603-603. | 2.8 | 0 |
| 284 | Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. <i>Oncogene</i> , 2004, 23, 2264-2274. | 5.9 | 71 |
| 285 | Medicine: Profile of a tumour. <i>Nature</i> , 2004, 428, 379-382. | 27.8 | 20 |
| 286 | CHEK2 1100delC is not a risk factor for male breast cancer population. <i>International Journal of Cancer</i> , 2004, 108, 475-476. | 5.1 | 55 |
| 287 | CHEK2 variant I157T may be associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2004, 111, 543-547. | 5.1 | 134 |
| 288 | A strategy for identifying putative causes of gene expression variation in human cancers. <i>Journal of the Franklin Institute</i> , 2004, 341, 77-88. | 3.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 289 | High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. <i>Neoplasia</i> , 2004, 6, 240-247. | 5.3 | 110 |
| 290 | BRCA2 Mutations in 154 Finnish Male Breast Cancer Patients. <i>Neoplasia</i> , 2004, 6, 541-545. | 5.3 | 33 |
| 291 | Are data from different gene expression microarray platforms comparable?. <i>Genomics</i> , 2004, 83, 1164-1168. | 2.9 | 179 |
| 292 | High-throughput RNAi screening identifies sensitizing targets to improve doxorubicin chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 9543-9543. | 1.6 | 0 |
| 293 | Title is missing!. <i>Machine Learning</i> , 2003, 52, 45-66. | 5.4 | 44 |
| 294 | Androgen Receptor Gene Alterations in Finnish Male Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 167-170. | 2.5 | 34 |
| 295 | Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. <i>Prostate</i> , 2003, 57, 280-289. | 2.3 | 47 |
| 296 | Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. <i>Oncogene</i> , 2003, 22, 2021-2033. | 5.9 | 415 |
| 297 | High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20. | 21.4 | 1,547 |
| 298 | RNAi Microarray Analysis in Cultured Mammalian Cells. <i>Genome Research</i> , 2003, 13, 2341-2347. | 5.5 | 173 |
| 299 | Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. <i>American Journal of Human Genetics</i> , 2003, 72, 1117-1130. | 6.2 | 3,105 |
| 300 | Candidate Genes for Testicular Cancer Evaluated by In Situ Protein Expression Analyses on Tissue Microarrays. <i>Neoplasia</i> , 2003, 5, 397-404. | 5.3 | 46 |
| 301 | BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. <i>Journal of Medical Genetics</i> , 2003, 40, 98e-98. | 3.2 | 22 |
| 302 | Topoisomerase-III α Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2003, 21, 4586-4591. | 1.6 | 74 |
| 303 | New Paraoxonase 1 Polymorphism I102V and the Risk of Prostate Cancer in Finnish Men. <i>Journal of the National Cancer Institute</i> , 2003, 95, 812-818. | 6.3 | 62 |
| 304 | A novel strategy for microarray quality control using Bayesian networks. <i>Bioinformatics</i> , 2003, 19, 2031-2038. | 4.1 | 48 |
| 305 | Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization. <i>Journal of Biomedical Optics</i> , 2002, 7, 109. | 2.6 | 20 |
| 306 | Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. <i>American Journal of Pathology</i> , 2002, 161, 1991-1996. | 3.8 | 494 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 307 | Expression of Bcl-2 Family Member Bid in Normal and Malignant Tissues. <i>Neoplasia</i> , 2002, 4, 129-140. | 5.3 | 82 |
| 308 | Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer. <i>American Journal of Human Genetics</i> , 2002, 70, 1299-1304. | 6.2 | 202 |
| 309 | A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer. <i>American Journal of Human Genetics</i> , 2002, 71, 432-438. | 6.2 | 402 |
| 310 | Simulation Toolbox for 3D-FISH Spot-Counting Algorithms. <i>Real Time Imaging</i> , 2002, 8, 203-212. | 1.6 | 15 |
| 311 | Cloning of <i>BCAS3</i> (17q23) and <i>BCAS4</i> (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 311-317. | 2.8 | 100 |
| 312 | A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. <i>Human Genetics</i> , 2002, 110, 111-121. | 3.8 | 66 |
| 313 | Androgen receptor CAG polymorphism and prostate cancer risk. <i>Human Genetics</i> , 2002, 111, 166-171. | 3.8 | 61 |
| 314 | Clinical and functional target validation using tissue and cell microarrays. <i>Current Opinion in Chemical Biology</i> , 2002, 6, 97-101. | 6.1 | 41 |
| 315 | Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. <i>Nature Genetics</i> , 2002, 30, 181-184. | 21.4 | 470 |
| 316 | Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints. <i>American Journal of Pathology</i> , 2001, 159, 2249-2256. | 3.8 | 521 |
| 317 | Gene-Expression Profiles in Hereditary Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 539-548. | 27.0 | 1,669 |
| 318 | Biochip technologies in cancer research. <i>Annals of Medicine</i> , 2001, 33, 142-147. | 3.8 | 79 |
| 319 | Tissue microarray technology for high-throughput molecular profiling of cancer. <i>Human Molecular Genetics</i> , 2001, 10, 657-662. | 2.9 | 479 |
| 320 | CGH, cDNA and Tissue Microarray Analyses Implicate <i>FGFR2</i> Amplification in a Small Subset of Breast Tumors. <i>Analytical Cellular Pathology</i> , 2001, 22, 229-234. | 2.1 | 60 |
| 321 | ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression. <i>Disease Markers</i> , 2001, 17, 115-120. | 1.3 | 32 |
| 322 | Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology?. <i>Advances in Anatomic Pathology</i> , 2001, 8, 14-20. | 4.3 | 133 |
| 323 | Genetic changes in familial prostate cancer by comparative genomic hybridization. <i>Prostate</i> , 2001, 46, 233-239. | 2.3 | 29 |
| 324 | Tissue microarrays (TMAs) for high-throughput molecular pathology research. <i>International Journal of Cancer</i> , 2001, 94, 1-5. | 5.1 | 220 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 325 | From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. <i>Seminars in Cancer Biology</i> , 2001, 11, 395-401. | 9.6 | 22 |
| 326 | Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. <i>Cancer Causes and Control</i> , 2001, 12, 223-230. | 1.8 | 42 |
| 327 | Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. <i>British Journal of Cancer</i> , 2001, 84, 116-119. | 6.4 | 38 |
| 328 | Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. <i>European Journal of Human Genetics</i> , 2001, 9, 773-779. | 2.8 | 23 |
| 329 | Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas—a possible mechanism for altering the nm23-H1 activity. <i>Oncogene</i> , 2001, 20, 6881-6890. | 5.9 | 52 |
| 330 | Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. <i>Oncogene</i> , 2001, 20, 6718-6723. | 5.9 | 122 |
| 331 | RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2001, 93, 153-154. | 6.3 | 1 |
| 332 | A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. <i>British Journal of Cancer</i> , 2001, 84, 1344-1347. | 6.4 | 47 |
| 333 | ANX7, a candidate tumor suppressor gene for prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 4575-4580. | 7.1 | 128 |
| 334 | Nationwide cancer family ascertainment using Finnish cancer registry data on family names and places of birth for 35,761 prostate cancer patients. <i>International Journal of Cancer</i> , 2000, 88, 307-312. | 5.1 | 6 |
| 335 | Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. <i>European Journal of Human Genetics</i> , 2000, 8, 757-763. | 2.8 | 75 |
| 336 | Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , 2000, 123, 128-132. | 1.0 | 60 |
| 337 | Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 9603-9608. | 7.1 | 153 |
| 338 | Distance-Based Reconstruction of Tree Models for Oncogenesis. <i>Journal of Computational Biology</i> , 2000, 7, 789-803. | 1.6 | 96 |
| 339 | Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1529-1531. | 6.3 | 159 |
| 340 | Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1252-1259. | 6.3 | 251 |
| 341 | High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer. <i>American Journal of Pathology</i> , 2000, 157, 787-794. | 3.8 | 232 |
| 342 | ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 164, 1992-1995. | 0.4 | 134 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 343 | Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p161. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735. | 3.6 | 97 |
| 344 | A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo. <i>Journal of Biological Chemistry</i> , 1999, 274, 34283-34293. | 3.4 | 190 |
| 345 | Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1758-1764. | 6.3 | 325 |
| 346 | Molecular cytogenetic analysis of 11 new breast cancer cell lines. <i>British Journal of Cancer</i> , 1999, 81, 1328-1334. | 6.4 | 186 |
| 347 | Inferring Tree Models for Oncogenesis from Comparative Genome Hybridization Data. <i>Journal of Computational Biology</i> , 1999, 6, 37-51. | 1.6 | 202 |
| 348 | Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 56-61. | 2.8 | 50 |
| 349 | High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 1999, 154, 981-986. | 3.8 | 376 |
| 350 | Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735. | 3.6 | 76 |
| 351 | Evidence for a prostate cancer susceptibility locus on the X chromosome. <i>Nature Genetics</i> , 1998, 20, 175-179. | 21.4 | 641 |
| 352 | Tissue microarrays for high-throughput molecular profiling of tumor specimens. <i>Nature Medicine</i> , 1998, 4, 844-847. | 30.7 | 3,661 |
| 353 | Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. <i>Cytogenetic and Genome Research</i> , 1998, 82, 189-191. | 1.1 | 11 |
| 354 | Positional cloning of ZNF217 and NABC1 : Genes amplified at 20q13.2 and overexpressed in breast carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8703-8708. | 7.1 | 271 |
| 355 | Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. <i>Human Molecular Genetics</i> , 1997, 6, 2309-2315. | 2.9 | 128 |
| 356 | Molecular genetics of human prostate cancer. <i>Current Opinion in Urology</i> , 1997, 7, 259-262. | 1.8 | 0 |
| 357 | ALB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. <i>Science</i> , 1997, 277, 965-968. | 12.6 | 1,514 |
| 358 | Androgen Receptor Gene Amplification in a Recurrent Prostate Cancer after Monotherapy with the Nonsteroidal Potent Antiandrogen Casodex (Bicalutamide) with a Subsequent Favorable Response to Maximal Androgen Blockade. <i>European Urology</i> , 1997, 31, 216-219. | 1.9 | 64 |
| 359 | Linking chromosomal clues. <i>Nature Genetics</i> , 1997, 15, 5-6. | 21.4 | 4 |
| 360 | Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. <i>British Journal of Cancer</i> , 1997, 75, 190-195. | 6.4 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 361 | Genome screening by comparative genomic hybridization. Trends in Genetics, 1997, 13, 405-409. | 6.7 | 272 |
| 362 | Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: A study by comparative genomic hybridization. , 1997, 19, 286-290. | | 53 |
| 363 | Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376. | | 74 |
| 364 | Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes and Cancer, 1997, 20, 383-391. | 2.8 | 106 |
| 365 | Quality control of CGH: Impact of metaphase chromosomes and the dynamic range of hybridization. Cytometry, 1997, 28, 198-205. | 1.8 | 66 |
| 366 | Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search. Science, 1996, 274, 1371-1374. | 12.6 | 717 |
| 367 | Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 1996, 89, 7-13. | 1.0 | 45 |
| 368 | Comparative genomic hybridization gaining in popularity. Trends in Genetics, 1996, 12, 237-238. | 6.7 | 5 |
| 369 | Fiber-FISH: experiences and a refined protocol. Genetic Analysis, Techniques and Applications, 1996, 12, 179-184. | 1.5 | 32 |
| 370 | Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. , 1996, 66, 6-10. | | 9 |
| 371 | Evaluation of camera requirements for comparative genomic hybridization. , 1996, 25, 394-398. | | 9 |
| 372 | c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. British Journal of Cancer, 1996, 73, 620-623. | 6.4 | 24 |
| 373 | Genetic Basis and Clonal Evolution of Human Prostate Cancer. Advances in Cancer Research, 1996, 68, 225-255. | 5.0 | 55 |
| 374 | Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively. Circulation, 1996, 93, 1079-1082. | 1.6 | 88 |
| 375 | Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 1996, 56, 57-63. | 1.2 | 17 |
| 376 | Molecular Cytogenetics of Solid Tumor Progression. , 1996, , 68-78. | | 2 |
| 377 | The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2p22. Cytogenetic and Genome Research, 1995, 68, 61-63. | 1.1 | 19 |
| 378 | Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes and Cancer, 1995, 12, 213-219. | 2.8 | 198 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 379 | Hardware and software requirements for quantitative analysis of comparative genomic hybridization. <i>Cytometry</i> , 1995, 19, 4-9. | 1.8 | 86 |
| 380 | Computer image analysis of comparative genomic hybridization. <i>Cytometry</i> , 1995, 19, 10-26. | 1.8 | 250 |
| 381 | In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nature Genetics</i> , 1995, 9, 401-406. | 21.4 | 1,316 |
| 382 | Mechanically stretched chromosomes as targets for high-resolution FISH mapping.. <i>Genome Research</i> , 1995, 5, 13-20. | 5.5 | 33 |
| 383 | A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. <i>Genomics</i> , 1995, 26, 134-137. | 2.9 | 50 |
| 384 | Visual Mapping by Fiber-FISH. <i>Genomics</i> , 1995, 30, 31-36. | 2.9 | 80 |
| 385 | Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. <i>Cancer</i> , 1994, 73, 652-658. | 4.1 | 98 |
| 386 | Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 231-243. | 2.8 | 1,215 |
| 387 | Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. <i>Cytometry</i> , 1994, 16, 93-99. | 1.8 | 116 |
| 388 | Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. <i>Cytometry</i> , 1994, 16, 250-255. | 1.8 | 33 |
| 389 | Physical Mapping of Chromosome 17 Cosmids by Fluorescence in Situ Hybridization and Digital Image Analysis. <i>Genomics</i> , 1994, 20, 125-128. | 2.9 | 35 |
| 390 | Molecular Cytogenetics of Human Breast Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1994, 59, 645-652. | 1.1 | 23 |
| 391 | Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 2156-2160. | 7.1 | 661 |
| 392 | Consensus review of the clinical utility of dna content cytometry in prostate cancer. <i>Cytometry</i> , 1993, 14, 497-500. | 1.8 | 120 |
| 393 | Extrachromosomal gene amplification in acute myeloid leukemia; Characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 185-189. | 2.8 | 44 |
| 394 | Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. <i>Human Pathology</i> , 1993, 24, 1348-1353. | 2.0 | 10 |
| 395 | Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 1993, 11, 36-43. | 1.6 | 110 |
| 396 | Association of Overexpression of Tumor Suppressor Protein p53 With Rapid Cell Proliferation and Poor Prognosis in Node-Negative Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1109-1114. | 6.3 | 337 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 397 | Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation. <i>Journal of the National Cancer Institute</i> , 1992, 84, 883-887. | 6.3 | 299 |
| 398 | ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5321-5325. | 7.1 | 493 |
| 399 | Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1992, 60, 190-193. | 1.1 | 43 |
| 400 | Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. <i>Science</i> , 1992, 258, 818-821. | 12.6 | 3,065 |
| 401 | Molecular cytogenetics: Diagnosis and prognostic assessment. <i>Current Opinion in Biotechnology</i> , 1992, 3, 623-631. | 6.6 | 25 |
| 402 | Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. <i>British Journal of Cancer</i> , 1991, 64, 578-582. | 6.4 | 49 |
| 403 | Cigarette Smoking Alters Sympathoadrenal Regulation by Decreasing the Density of β ² -Adrenoceptors. A Study of Monitored Smoking Cessation. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, 923-928. | 1.9 | 44 |
| 404 | Association of <i>erbB-2</i> protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. <i>International Journal of Cancer</i> , 1991, 49, 650-655. | 5.1 | 352 |
| 405 | Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. <i>Cytometry</i> , 1991, 12, 413-421. | 1.8 | 68 |
| 406 | Primary undifferentiated small cell carcinoma of the esophagus: Clinicopathological and flow cytometric evaluation of eight cases. <i>Journal of Surgical Oncology</i> , 1991, 46, 174-177. | 1.7 | 45 |
| 407 | Flow Cytometric Analysis of Tumour dna Profile Related to Response to Radiotherapy and Survival in Inoperable Lung Cancer. <i>Acta Oncologica</i> , 1990, 29, 983-988. | 1.8 | 14 |
| 408 | Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. <i>British Journal of Cancer</i> , 1990, 62, 142-146. | 6.4 | 81 |
| 409 | Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 1990, 17, 59-61. | 2.5 | 21 |
| 410 | Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival. <i>Journal of Pathology</i> , 1990, 162, 295-301. | 4.5 | 73 |
| 411 | Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells. <i>The Histochemical Journal</i> , 1990, 22, 498-506. | 0.6 | 34 |
| 412 | Chapter I. Biology and natural history of breast cancer. <i>International Journal of Cancer</i> , 1990, 46, 5-21. | 5.1 | 51 |
| 413 | Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. <i>Cancer</i> , 1990, 65, 1180-1184. | 4.1 | 169 |
| 414 | Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry. <i>Cancer</i> , 1990, 63, 1761-1767. | 4.1 | 76 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 415 | Analysis of DNA synthesis in herpes simplex virus infected cells by dual parameter flow cytometry. Archives of Virology, 1989, 107, 215-223. | 2.1 | 5 |
| 416 | Different opinions on classification of DNA histograms produced from paraffin-embedded tissue. Cytometry, 1989, 10, 711-717. | 1.8 | 77 |
| 417 | Flow cytometric DNA analysis of 199 histologically favourable or unfavourable non-Hodgkin lymphomas. Journal of Pathology, 1989, 157, 27-36. | 4.5 | 50 |
| 418 | Serum CA 125 in acute pelvic inflammatory disease. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 574-579. | 2.3 | 25 |
| 419 | Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1989, 32, 247-251. | 1.1 | 9 |
| 420 | Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. Clinical Immunology and Immunopathology, 1989, 52, 406-413. | 2.0 | 6 |
| 421 | Prognostic Assessment in Stage I Ovarian Cancer Using a Discriminant Analysis with Clinicopathological and DNA Flow Cytometric Data. Gynecologic and Obstetric Investigation, 1989, 27, 213-216. | 1.6 | 12 |
| 422 | Prognostic significance of dna index, multiploidy, and S-phase fraction in ovarian cancer. Cancer, 1988, 61, 334-339. | 4.1 | 197 |
| 423 | Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer. Cancer, 1988, 62, 2183-2190. | 4.1 | 240 |
| 424 | Elevated serum hmfg antigen levels in breast and ovarian cancer patients measured with a sandwich elisa. International Journal of Cancer, 1988, 41, 28-33. | 5.1 | 8 |
| 425 | DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. International Journal of Cancer, 1988, 42, 697-702. | 5.1 | 21 |
| 426 | Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry, 1988, 9, 164-169. | 1.8 | 228 |
| 427 | Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. British Journal of Cancer, 1988, 58, 213-215. | 6.4 | 64 |
| 428 | Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. Atherosclerosis, 1988, 69, 257-268. | 0.8 | 35 |
| 429 | DNA Ploidy Level and Cell Cycle Distribution in Ovarian Cancer. International Journal of Gynecological Pathology, 1988, 7, 1-11. | 1.4 | 24 |
| 430 | Correlation between Serum Tumor Marker Levels and Tumor Proliferation in Small Cell Lung Cancer. Tumor Biology, 1988, 9, 287-292. | 1.8 | 10 |
| 431 | Nuclear DNA content of non-endemic Burkitt's lymphoma.. Journal of Clinical Pathology, 1987, 40, 1201-1205. | 2.0 | 13 |
| 432 | Tumour DNA ploidy as an independent prognostic factor in breast cancer. British Journal of Cancer, 1987, 56, 637-642. | 6.4 | 163 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 433 | Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 277-282. | 0.7 | 134 |
| 434 | Herpes virus specified early proteins induce cellular DNA synthesis in virus infected cervical cancer cells. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1771. | 0.7 | 0 |
| 435 | Nuclear DNA content characteristics of 129 high grade malignancy non-Hodgkin lymphomas. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1775. | 0.7 | 0 |
| 436 | Prognostic impact of DNA-ploidy and S-phase fraction. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1765. | 0.7 | 0 |
| 437 | Growth properties and composition of cytoskeletal and cytocontractile proteins in aortic cells isolated and cultured from normal and atherosclerotic rabbits. <i>Atherosclerosis</i> , 1984, 52, 13-26. | 0.8 | 18 |
| 438 | Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population. , 0, , . | | 2 |